These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.